SCREENING FOR GERM LINE TP53 MUTATIONS IN BREAST-CANCER PATIENTS

被引:0
|
作者
BORRESEN, AL
ANDERSEN, TI
GARBER, J
BARBIERPIRAUX, N
THORLACIUS, S
EYFJORD, J
OTTESTAD, L
SMITHSORENSEN, B
HOVIG, E
MALKIN, D
FRIEND, SH
机构
[1] NORWEGIAN RADIUM HOSP,DEPT ONCOL,OSLO 3,NORWAY
[2] HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR CANC,BOSTON,MA 02114
[3] HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115
[4] ICELAND CANC SOC,REYKJAVIK,ICELAND
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The constant denaturant gel electrophoresis technique was used to screen for TP53 germ line mutations in 237 women with breast carcinoma (167 unselected patients, 30 patients with at least one first-degree relative with breast cancer, and 40 women diagnosed with breast cancer before age 35). A germ line mutation at codon 181 was noted in one of the unselected patients and a codon 245 mutation in one of the early-onset patients. Both had a family history of breast cancer and other malignancies suggestive of Li-Fraumeni syndrome. The codon 245 mutation was also present in this patient's affected mother.
引用
收藏
页码:3234 / 3236
页数:3
相关论文
共 50 条
  • [31] Impact of TP53 mutations in Triple Negative Breast Cancer
    Zahi I. Mitri
    Nour Abuhadra
    Shaun M. Goodyear
    Evthokia A. Hobbs
    Andy Kaempf
    Alastair M. Thompson
    Stacy L. Moulder
    npj Precision Oncology, 6
  • [32] TP53 mutations as a prognostic factor in women with breast cancer
    Marie Lofthouse
    Nature Clinical Practice Oncology, 2005, 2 (9): : 428 - 429
  • [33] Impact of TP53 mutations in Triple Negative Breast Cancer
    Mitri, Zahi, I
    Abuhadra, Nour
    Goodyear, Shaun M.
    Hobbs, Evthokia A.
    Kaempf, Andy
    Thompson, Alastair M.
    Moulder, Stacy L.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [34] Clinical implications of germline mutations in breast cancer: TP53
    Schon, Katherine
    Tischkowitz, Marc
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 417 - 423
  • [35] Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
    Kyndi, M
    Alsner, J
    Hansen, LL
    Sorensen, FB
    Overgaard, J
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S54 - S54
  • [36] TP53 and mutations in human cancer
    Szymanska, K
    Hainaut, P
    ACTA BIOCHIMICA POLONICA, 2003, 50 (01) : 231 - 238
  • [37] IDENTIFICATION OF GERM-LINE MUTATIONS IN BRCA1, MLM, AND TP53 IN BREAST OVARIAN-CANCER PRONE KINDREDS
    DALY, M
    BERMAN, DB
    WAGNER, J
    MASNY, A
    VANDERVEER, L
    SCHULTZ, DC
    GODWIN, AK
    AMERICAN JOURNAL OF HUMAN GENETICS, 1995, 57 (04) : 17 - 17
  • [38] Prevalence of germline TP53 mutations in HER2+ breast cancer patients
    Michelle G. Rath
    Serena Masciari
    Rebecca Gelman
    Alexander Miron
    Penelope Miron
    Kathleen Foley
    Andrea L. Richardson
    Ian E. Krop
    Sigitas J. Verselis
    Deborah A. Dillon
    Judy E. Garber
    Breast Cancer Research and Treatment, 2013, 139 : 193 - 198
  • [39] Prevalence of germline TP53 mutations in HER2+breast cancer patients
    Rath, Michelle G.
    Masciari, Serena
    Gelman, Rebecca
    Miron, Alexander
    Miron, Penelope
    Foley, Kathleen
    Richardson, Andrea L.
    Krop, Ian E.
    Verselis, Sigitas J.
    Dillon, Deborah A.
    Garber, Judy E.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (01) : 193 - 198
  • [40] TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer (Review)
    Huszno, Joanna
    Grzybowska, Ewa
    ONCOLOGY LETTERS, 2018, 16 (01) : 34 - 40